A multinational, multicenter, single blood sampling exploratory pharmacogenetic study of the REGARD (the REbif vs Glatiramer Acetate in Relapsing MS Disease) trial - REGARD-PGx
- Conditions
- Multiple SclerosisMedDRA version: 12.0Level: PTClassification code 10028245Term: Multiple sclerosis
- Registration Number
- EUCTR2009-016087-37-FR
- Lead Sponsor
- Merck Serono S.A. - Geneva
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 0
For inclusion in the trial, all of the following inclusion criteria must be fulfilled:
The subject
1.Was randomized in the REGARD 24735 study
2.Is willing and able to comply with the protocol
3.Has given written informed consent before performing any trial-related activities.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Subjects are not eligible for this trial if they fulfill any of the following exclusion criteria:
The subject
1.Is unwilling or unable to participate in the trial.
2.Was already included in the initial REGARD PGx-substudy.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method